

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4360814

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JONATHAN ADAMS	04/06/2017
PETER JEFFREY ADAMS	04/06/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ADAMS PHARMACEUTICALS LLC
<b>Street Address:</b>	417 RIVERSIDE DRIVE, SUITE 5F
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10025
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15482073
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	703-740-8322
<b>Email:</b>	patent@maierandmaier.com
<b>Correspondent Name:</b>	MAIER & MAIER, PLLC
<b>Address Line 1:</b>	345 SOUTH PATRICK STREET
<b>Address Line 4:</b>	ALEXANDRIA, VIRGINIA 22314
<b>ATTORNEY DOCKET NUMBER:</b>	08860001US
<b>NAME OF SUBMITTER:</b>	CHRISTOPHER J, MAIER
<b>SIGNATURE:</b>	/Christopher J. MAIER/
<b>DATE SIGNED:</b>	04/10/2017
<b>Total Attachments: 2</b>	
source=08860001US_Assignment#page1.tif	
source=08860001US_Assignment#page2.tif	

**DECLARATION AND ASSIGNMENT**

Title of Invention: PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS

**DECLARATION**

As a below named inventor, I hereby declare that:

This declaration is directed to:

- The attached application, or
- United States application or PCT international application number \_\_\_\_\_, filed on \_\_\_\_\_

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understood the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT**

WHEREAS, I, Peter Jeffrey Adams, whose post office address is c/o Adams Pharmaceuticals LLC, 417 Riverside Drive, Suite 5F, New York, NY 10025, hereinafter referred to as ASSIGNOR, am the owner of useful improvements in PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS (hereinafter referred to as the INVENTION) for which the above application for United States Letters Patent was filed on: 07-APR-2017 Serial No.: 15482073; or established by PCT International Patent Application No.: \_\_\_\_\_ filed: \_\_\_\_\_ designating the United States of America;

WHEREAS, Adams Pharmaceuticals LLC, whose post office address is 417 Riverside Drive, Suite 5F, New York, NY 10025, hereinafter referred to as ASSIGNEE, is desirous of acquiring the entire right, title and interest in and to the same in the United States;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, ASSIGNOR, by these presents do sell, assign and transfer unto said ASSIGNEE, the entire right, title, and interest in and to said INVENTION and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, ASSIGNOR hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said INVENTION, including additional documents that may be required to affirm the rights of ASSIGNEE in and to said INVENTION, all without further consideration. ASSIGNOR also agrees, without further consideration and at ASSIGNEE'S expense, to identify and communicate to ASSIGNEE at ASSIGNEE'S request documents and information concerning the INVENTION that are within ASSIGNOR'S possession or control, and to provide further assurances and testimony on behalf of ASSIGNEE that lawfully may be required of ASSIGNOR in respect of the prosecution, maintenance and defense of any patent application or patent encompassed within the terms of this instrument. ASSIGNOR'S obligations under this instrument shall extend to ASSIGNOR'S heirs, executors, administrators and other legal representatives.

ALSO, ASSIGNOR hereby authorizes and requests the Director of the U.S. Patent and Trademark office to issue any and all Letters Patent referred to above to ASSIGNEE, as the ASSIGNEE of the entire right, title and interest in and to the same, for ASSIGNEE'S sole use and behoof; and for the use and behoof of ASSIGNEE'S legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made.

ASSIGNOR authorizes any member of the firm of Maier & Maier, PLLC to insert or complete any information in this document needed to effect its recordal in the U.S. Patent and Trademark Office.

Legal Name of Inventor: Peter Jeffrey Adams

X   
Inventor's Signature

X April 6, 2017  
Date

**DECLARATION AND ASSIGNMENT**

Title of Invention: PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS

**DECLARATION**

As a below named inventor, I hereby declare that:

This declaration is directed to:

- The attached application, or
- United States application or PCT international application number \_\_\_\_\_, filed on \_\_\_\_\_

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understood the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT**

WHEREAS, I, Jonathan Adams, whose post office address is c/o Adams Pharmaceuticals LLC, 417 Riverside Drive, Suite 5F, New York, NY 10025, hereinafter referred to as ASSIGNOR, am the owner of useful improvements in PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS (hereinafter referred to as the INVENTION) for which the above application for United States Letters Patent was filed on: 07-APR-2017 Serial No.: 15482073; or established by PCT International Patent Application No.: \_\_\_\_\_ filed: \_\_\_\_\_ designating the United States of America;

WHEREAS, Adams Pharmaceuticals LLC, whose post office address is 417 Riverside Drive, Suite 5F, New York, NY 10025, hereinafter referred to as ASSIGNEE, is desirous of acquiring the entire right, title and interest in and to the same in the United States;


NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, ASSIGNOR, by these presents do sell, assign and transfer unto said ASSIGNEE, the entire right, title, and interest in and to said INVENTION and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, ASSIGNOR hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said INVENTION, including additional documents that may be required to affirm the rights of ASSIGNEE in and to said INVENTION, all without further consideration. ASSIGNOR also agrees, without further consideration and at ASSIGNEE'S expense, to identify and communicate to ASSIGNEE at ASSIGNEE'S request documents and information concerning the INVENTION that are within ASSIGNOR'S possession or control, and to provide further assurances and testimony on behalf of ASSIGNEE that lawfully may be required of ASSIGNOR in respect of the prosecution, maintenance and defense of any patent application or patent encompassed within the terms of this instrument. ASSIGNOR'S obligations under this instrument shall extend to ASSIGNOR'S heirs, executors, administrators and other legal representatives.

ALSO, ASSIGNOR hereby authorizes and requests the Director of the U.S. Patent and Trademark office to issue any and all Letters Patent referred to above to ASSIGNEE, as the ASSIGNEE of the entire right, title and interest in and to the same, for ASSIGNEE'S sole use and behoof, and for the use and behoof of ASSIGNEE'S legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made.

ASSIGNOR authorizes any member of the firm of Maier & Maier, PLLC to insert or complete any information in this document needed to effect its recordal in the U.S. Patent and Trademark Office.

Legal Name of Inventor: Jonathan Adams

X   
\_\_\_\_\_  
Inventor's Signature

X 4/6/2017  
\_\_\_\_\_  
Date